IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Protective Immunity Project 02 (PIP-02)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Influenza (Flu) vaccine is recommended for kidney transplant patients who are at least 6 months post-transplant. The influenza vaccine stimulates the immune system to builds protective antibodies against the flu virus.
Previous research has shown that adult kidney transplant patients are not able to form as much of these protective antibodies as compared to healthy volunteers. Research has also suggested that different immunosuppressive medicines may have different effects on antibody formation. In this study, we hope to evaluate these differences in more detail.
In recent years, increasingly effective, but also increasingly complex, immunosuppressive regimens have been developed, however, there has been little detailed systematic study of the immune changes that occur in response to vaccination with these newer immunosuppressive regimens.Current policies on vaccination of transplant recipients are generic and continue to be based on old concepts rather than on any new understanding of the effects of these newer therapies on the immune system.
We hope to improve our understanding of the effects of the immunosuppressive regimens in use today (calcineurin-inhibitor, or CNI, and sirolimus-based regimens) on immune response to flu vaccine. Such knowledge will be critical to helping clinicians develop strategies for getting desirable immune responses while not causing rejection.
| Condition |
|---|
| Kidney Transplant Immunology Immunosuppression |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | A Prospective Comparison of the Magnitude and Character of the Immune Response to Influenza Vaccine in Immunosuppressed Renal Transplant Patients and Healthy Age-matched Volunteers |
- To determine the effect of immunosuppressive regimens on the magnitude and character of the adaptive immune response to flu vaccine [ Time Frame: 7, 14, 28 and 90 days post vaccination ]
- To determine the effects of chronic immunosuppressive therapies on innate immunity during response to flu vaccine [ Time Frame: 7, 14, 28 and 90 days post vaccination ]
- To define the transcriptional and protein signatures of the response to flu vaccination in patients on conventional immunosuppressive regimens compared to healthy volunteers [ Time Frame: 7, 14, 28 and 90 days post vaccination ]
Biospecimen Retention: Samples Without DNA
| Enrollment: | 97 |
| Study Start Date: | November 2006 |
| Study Completion Date: | October 2011 |
| Primary Completion Date: | February 2010 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
tacrolimus
Recipients of primary deceased or living donor renal transplant maintained on immunosuppressive regimen utilizing tacrolimus
|
|
sirolimus
Recipients of primary deceased or living donor renal transplant maintained on immunosuppressive regimen utilizing sirolimus
|
|
Healthy controls
Age, gender- and race-matched individuals, not on immunosuppressive medications
|
Eligibility| Ages Eligible for Study: | 18 Years to 59 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Male or female patients between 18 and 59 years of age
- Greater than six months post deceased or living donor renal transplant
- Patients capable of understanding the purposes and risks of the study, who can give written informed consent and who are willing to participate in and comply with the study.
- Patients with no known contraindications to flu vaccine (e.g. egg allergy, prior serious adverse reaction to flu vaccine, current febrile illness, marked leukopenia (WBC < 2500 cells/ml)
- Women of childbearing potential must have a negative serum pregnancy test within 7 days of study enrollment and must not be breast-feeding.
Exclusion Criteria:
1. Patients with evidence of an active systemic infection
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT00833651
| United States, Georgia | |
| Emory University | |
| Atlanta, Georgia, United States, 30322 | |
| Principal Investigator: | Christian P. Larsen, MD, DPhil | Emory University |
| Principal Investigator: | Kenneth E Kokko, MD, PhD | Emory University |
More Information
| Responsible Party: | Christian P Larsen, MD, PhD, Chairman, Dept. of Surgery, Emory University |
| ClinicalTrials.gov Identifier: | NCT00833651 History of Changes |
| Other Study ID Numbers: |
IRB00024793 PIP-02 ( Other Identifier: Other ) |
| Study First Received: | January 30, 2009 |
| Last Updated: | November 21, 2013 |
Keywords provided by Christian P Larsen, MD, PhD, Emory University:
|
Transplant Immunology Immunosuppression |
ClinicalTrials.gov processed this record on August 18, 2017